Cytomegalovirus surface glycoprotein (CMV-SA)

Cytomegalovirus (CMV) surface antigens, primarily the envelope glycoproteins, are essential components of the Human Cytomegalovirus (HCMV) virion that facilitate host cell recognition, attachment, and entry (UniProt, 2024). The most significant targets include Glycoprotein B (gB), which acts as the primary viral fusogen, and the Pentameric Complex (comprising gH, gL, UL128, UL130, and UL131A), which is required for entry into epithelial, endothelial, and myeloid cells (PubMed, 2015). These surface proteins are the primary targets for neutralizing antibodies generated by the host immune system and are the focus of modern vaccine and passive immunotherapy strategies (PubMed, 2019). In clinical practice, targeting these antigens aims to prevent primary infection, reactivation, or reinfection, particularly in high-risk populations such as pregnant women and transplant recipients (NIH, 2023). Therapeutic interventions include polyclonal intravenous immunoglobulin (IVIG) and various monoclonal antibodies or mRNA-based vaccines currently in development (Moderna, 2024). By blocking these antigens, the virus is prevented from penetrating the host cell membrane, thereby neutralizing its infectivity and limiting systemic spread (PubMed, 2021).

Other names

Human cytomegalovirus envelope glycoproteinsHCMV surface antigensGlycoprotein B (gB)Glycoprotein H (gH)Glycoprotein L (gL)Pentameric complex (gH/gL/UL128/UL130/UL131A)Trimeric complex (gH/gL/gO)

Neutralization of viral entry and inhibition of membrane fusion by blocking interaction with host cell receptors (PubMed, 2019).